AR-Targeting PROTAC Compounds With Improved Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PROTAC molecules for androgen receptor (AR) degradation suffer from large molecular weight and poor solubility, limiting their effectiveness in treating castration-resistant prostate cancer (CRPC) and metastatic castration-resistant prostate cancer (mCRPC).
Innovation Solution
Development of novel compounds represented by formulas (I) and (II) with specific structural variations, including heterocyclic rings and linkers, to enhance metabolic stability and drug activity, utilizing the ubiquitin-proteasome system for AR degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PROTAC molecules are designed for androgen receptor degradation, then the androgen receptor can be degraded, but the molecular weight becomes large and solubility deteriorates
Solution Approach 1:
The PROTAC molecule is divided into three functional segments: a VHL ligand portion (binds to E3 ligase), a linker portion (connects segments), and a Cereblon ligand portion (binds to target AR). This segmentation allows each part to be optimized independently for its specific function while maintaining overall molecular manageability.
Solution Approach 2:
The linker portion acts as an intermediary between the VHL ligand and Cereblon ligand, providing spatial arrangement and orientation that facilitates the tripartite complex formation with E3 ligase and target AR, while maintaining appropriate distance and flexibility.
2Reliability
If PROTAC molecules are designed for androgen receptor degradation, then the androgen receptor can be degraded, but solubility becomes poor
Solution Approach 1:
Different portions of the PROTAC molecule have different chemical properties optimized for their specific functions: the VHL ligand and Cereblon ligand are designed with specific pharmacological properties for target binding, while the linker portion is designed with appropriate hydrophilicity and flexibility. This local optimization balances solubility requirements with binding efficacy.
3Reliability
If conventional PROTAC structures are used, then AR degradation can be achieved, but metabolic stability is reduced
Solution Approach 1:
The linker portion's chemical structure is carefully designed with specific parameters including bond lengths, bond angles, and rotational barriers to optimize both the spatial arrangement for AR degradation and the metabolic stability. The linker's chemical composition is selected to resist metabolic degradation while maintaining flexibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compounds improve the metabolic stability and drug activity of PROTAC molecules, potentially offering better treatment options for CRPC and mCRPC by effectively degrading the androgen receptor.
Implementation Method 1
PROTAC technology mainly relies on the intracellular ubiquitin-proteasome system. This system is the 'cleaner' in the cell, and the main function of the ubiquitination system is to ubiquitinate the denatured, mutated or harmful proteins in the cell. Ubiquitinated proteins are degraded by the proteasome system inside the cell.
Data Source
AI summary
Provided are a protein degradation agent compound preparation method and application; specifically, provided are the compound represented by formula (I) and a pharmacologically acceptable salt thereof, and an application of said compound in the degradation of androgen receptor (AR).